English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Purpose  To evaluate the efficacy of photobiomodulation ( PBM ) treatment for patients with dry age‐related macular degeneration ( AMD ).    Methods  Assessments on 42 eyes with dry  AMD  (age related eye disease study (AREDS) 2–4) were conducted. Multiwavelength light emitting diode ( LED ) light comprising of yellow (590 nm), red (670 nm) and near‐infrared (790 nm) bandwidths was applied to subjects’ eyes for a treatment course of 3 weeks. Outcome measures were changes in best‐corrected visual acuity ( BCVA ), contrast sensitivity ( CS ), drusen volume and central drusen thickness.    Results  Significant improvement in mean  BCVA  of 5.90 letters (p < 0.001) was seen on completion of the 3‐week treatment and 5.14 letters (p < 0.001) after 3 months. Contrast sensitivity improved significantly (log unit improvement of 0.11 (p = 0.02) at 3 weeks and 3 months (log unit improvement of 0.16 (p = 0.02) at three cycles per degree. Drusen volume decreased by 0.024 mm 3  (p < 0.001) and central drusen thickness was significantly reduced by a mean of 3.78  μ m (p < 0.001), while overall central retinal thickness and retinal volume remained stable.    Conclusion  This is the first study demonstrating improvements in functional and anatomical outcomes in dry  AMD  subjects with  PBM  therapy. These findings corroborate an earlier pilot study that looked at functional outcome measures. The addition of anatomical evidence contributes to the basis for further development of a non‐invasive  PBM  treatment for dry  AMD .

Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age‐related macular degeneration